Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SurModics, a provider of drug delivery and surface modification technologies, and Nexeon MedSystems, a developer of medical devices for the treatment of cardiovascular and peripheral vascular disease, have signed a licensing agreement to collaborate on the development of a novel stent system for the treatment of renal artery disease.
Subscribe to our email newsletter
This agreement is in addition to the prior one announced in July 2007 to develop a novel stent system for coronary artery disease, which is now in clinical trials. SurModics is also an equity investor in Nexeon MedSystems.
This novel stent system for the renal arteries will incorporate SurModics’s proprietary Finale prohealing coating technology and Nexeon’s bare metal Kodiak peripheral stent technology. Terms of the agreement were not disclosed.
Bruce Barclay, president and CEO of SurModics, said: “Nexeon has demonstrated a strong capability of developing products and rapidly advancing them into clinical trials. We are encouraged that Nexeon is extending its portfolio of products that leverages our Finale prohealing technology beyond coronary stents into renal stents.”